See more : Sakae Electronics Corporation (7567.T) Income Statement Analysis – Financial Results
Complete financial analysis of IN8bio, Inc. (INAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IN8bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sambhaav Media Limited (SAMBHAAV.BO) Income Statement Analysis – Financial Results
- R. C. Core Co., Ltd. (7837.T) Income Statement Analysis – Financial Results
- VIZSLA ROYALTIES CORP (VROY.V) Income Statement Analysis – Financial Results
- Raffles Education Corporation Limited (RFLFF) Income Statement Analysis – Financial Results
- Pet Valu Holdings Ltd. (PET.TO) Income Statement Analysis – Financial Results
IN8bio, Inc. (INAB)
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.50M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| Gross Profit | -2.50M | -1.10M | -251.00K | -96.00K | -96.00K | -96.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.83M | 14.06M | 7.35M | 5.38M | 2.36M | 581.00K |
| General & Administrative | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -63.00K |
| Operating Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Cost & Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K |
| Depreciation & Amortization | 1.83M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| EBITDA | -28.50M | -27.42M | -14.40M | -8.47M | -5.04M | -1.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -30.34M | -28.52M | -14.65M | -8.56M | -5.13M | -2.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 330.00K | 0.00 | 0.00 | 0.00 | 0.00 | -77.00K |
| Income Before Tax | -30.01M | -28.52M | -14.65M | -8.56M | -5.13M | -2.08M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.10M | 551.44K | -118.30K | -68.00K | -63.00K |
| Net Income | -30.01M | -27.42M | -14.65M | -8.56M | -5.13M | -2.08M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| EPS Diluted | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| Weighted Avg Shares Out | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
| Weighted Avg Shares Out (Dil) | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial INB-100 trial currently expanding enrollment up to...
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support the observed 100% progression-free survival in AML patients as of August 30,...
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the: H.C.
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025. Early clinical data from investigator sponsored trials demonstrates prolonged relapse-free survival across...
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the...
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion...
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen) Majority of fully dosed patients exceeded the expected median PFS based on age and tumor...
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May...
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming presentation of updated results from its fully enrolled Phase 1 study of INB-200 at...
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid,...
Source: https://incomestatements.info
Category: Stock Reports